Bosaeed, M., & Kumar, D. (2018). Seasonal influenza vaccine in immunocompromised persons. Human vaccines & immunotherapeutics, 14(6), 1311-1322.

Centers For Disease Control and Prevention. (2019). Influenza (Flu).

Centers For Disease Control and Prevention. (2019). Flu Symptoms & Complications

Center for Infectious Disease Research and Policy. (2012). The Compelling Need for Game-Changing Influenza Vaccines [PDF].

  DeStefano, F., Bodenstab, H. M., & Offit, P. A. (2019). Principal Controversies in Vaccine Safety in the United States. Clinical Infectious Diseases.

Englund, J. A., Walter, E., Black, S., Blatter, M., Nyberg, J., Ruben, F. L., … & GRC28 Study Team. (2010). Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. The Pediatric infectious disease journal, 29(2), 105-110

 Greene, S. K., Rett, M. D., Vellozzi, C., Li, L., Kulldorff, M., Marcy, S. M., … & Jackson, M. L. (2013). Guillain-Barré syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009–2011. PLoS One, 8(6), e67185.

Heinonen, S., Silvennoinen, H., Lehtinen, P., Vainionpää, R., Ziegler, T., & Heikkinen, T. (2011). Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. The Lancet infectious diseases, 11(1), 23-29.

 Jefferson, T., Smith, S., Demicheli, V., Harnden, A., & Rivetti, A. (2005). Safety of influenza vaccines in children. The Lancet, 366(9488), 803-804

Kadar, M. (n.d.). Global Vaccine Market Features and Trends [PDF].

Principi, N., & Esposito, S. (2018). Vaccine-preventable diseases, vaccines and Guillain-Barre’syndrome. Vaccine.

Ruben, F. L. (2004). Inactivated influenza virus vaccines in children. Clinical infectious diseases, 38(5), 678-688

 Strijbos, E., Tannemaat, M. R., Alleman, I., de Meel, R. H., Bakker, J. A., van Beek, R., … & Verschuuren, J. J. (2019). A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine, 37(7), 919-925.

Treanor, J. J., El Sahly, H., King, J., Graham, I., Izikson, R., Kohberger, R., … & Cox, M. (2011). Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine, 29(44), 7733-7739.

van Doorn, E., Pleguezuelos, O., Liu, H., Fernandez, A., Bannister, R., Stoloff, G., … & Hak, E. (2017). Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial. BMC infectious diseases, 17(1), 241.

Vellozzi, C., Iqbal, S., & Broder, K. (2014). Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clinical infectious diseases, 58(8), 1149-1155.